non-enantiomer

the drug candidate was identified as a non-enantiomer, complicating the synthesis process.

our research focused on the separation of a non-enantiomer mixture using chiral chromatography.

the non-enantiomer exhibited significantly lower biological activity compared to the desired enantiomer.

we analyzed the product to confirm the absence of a non-enantiomer impurity.

the non-enantiomer's properties were thoroughly investigated for potential applications.

the synthesis yielded a racemic mixture containing a non-enantiomer component.

regulatory guidelines require strict control of non-enantiomer levels in pharmaceutical products.

the chiral shift revealed the presence of a non-enantiomer in the sample.

we developed a new method for selectively removing the non-enantiomer from the reaction mixture.

the non-enantiomer's impact on the overall reaction kinetics was carefully assessed.

the presence of a non-enantiomer can affect the drug's efficacy and safety profile.